Your browser doesn't support javascript.
loading
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Tewari, Krishnansu S; Sill, Michael W; Penson, Richard T; Huang, Helen; Ramondetta, Lois M; Landrum, Lisa M; Oaknin, Ana; Reid, Thomas J; Leitao, Mario M; Michael, Helen E; DiSaia, Philip J; Copeland, Larry J; Creasman, William T; Stehman, Frederick B; Brady, Mark F; Burger, Robert A; Thigpen, J Tate; Birrer, Michael J; Waggoner, Steven E; Moore, David H; Look, Katherine Y; Koh, Wui-Jin; Monk, Bradley J.
Afiliação
  • Tewari KS; Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA. Electronic address: ktewari@uci.edu.
  • Sill MW; Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY, USA.
  • Penson RT; Massachusetts General Hospital, Boston, MA, USA.
  • Huang H; Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY, USA.
  • Ramondetta LM; MD Anderson Cancer Center, Houston, TX, USA.
  • Landrum LM; Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK, USA.
  • Oaknin A; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Reid TJ; University of Cincinnati College of Medicine, Cincinnati, OH, USA; Women's Cancer Center at Kettering, Cincinnati, OH, USA.
  • Leitao MM; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Michael HE; Indiana University School of Medicine, Indianapolis, IN, USA.
  • DiSaia PJ; Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA.
  • Copeland LJ; Ohio State University Medical Center, Columbus, OH, USA.
  • Creasman WT; Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA.
  • Stehman FB; Indiana University School of Medicine, Indianapolis, IN, USA.
  • Brady MF; Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY, USA.
  • Burger RA; Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA, USA.
  • Thigpen JT; University of Mississippi Medical Center, Jackson, MS, USA.
  • Birrer MJ; Massachusetts General Hospital, Boston, MA, USA.
  • Waggoner SE; Department of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, OH, USA.
  • Moore DH; Franciscan St Francis Health, Indianapolis, IN, USA.
  • Look KY; Genentech, South San Francisco, CA, USA.
  • Koh WJ; Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
  • Monk BJ; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, AZ, USA.
Lancet ; 390(10103): 1654-1663, 2017 Oct 07.
Article em En | MEDLINE | ID: mdl-28756902
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Bevacizumab Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Bevacizumab Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2017 Tipo de documento: Article